A Open-label Randomized controlled trial to compare the efficacy of Dapagliflozin and Teneligliptin on liver fat reduction and on Metabolic Parameters in type 2 Diabetes patients with MAFLD"

This Open-label, randomized controlled trial  will compare the efficacy of dapagliflozin and teneligliptin on liver fat reduction and metabolic parameters in patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). MAFLD is a prevalent liver condition strongly associated with metabolic disorders such as diabetes, obesity, and hypertension. While both dapagliflozin (SGLT2 inhibitor) and teneligliptin (DPP-4 inhibitor) are used for diabetes, emerging evidence suggests they may have additional benefits on liver health. This study aims to evaluate and compare the impact of these drugs on liver fat content, blood sugar levels, body mass index, liver enzymes, and blood pressure over three months. The findings could guide better treatment strategies for MAFLD in the Indian population.